Document Detail


Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.
MedLine Citation:
PMID:  18254018     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Osteoporosis is an abnormal reduction in bone mass and bone deterioration leading to increased fracture risk. Etidronate belongs to the bisphosphonate class of drugs which act to inhibit bone resorption by interfering with the activity of osteoclasts.
OBJECTIVES: To assess the efficacy of etidronate in the primary and secondary prevention of osteoporotic fractures in postmenopausal women.
SEARCH STRATEGY: We searched CENTRAL, MEDLINE and EMBASE for relevant randomized controlled trials published between 1966 to 2007.
SELECTION CRITERIA: Women receiving at least one year of etidronate for postmenopausal osteoporosis were compared to those receiving placebo and/or concurrent calcium/vitamin D. The outcome was fracture incidence.
DATA COLLECTION AND ANALYSIS: Study selection and data abstraction was done in duplicate. Meta-analysis of fracture outcomes was performed with data presented as relative risks and a relative change greater than 15% was considered clinically important. Study quality was assessed through the reporting of allocation concealment, blinding and withdrawals.
MAIN RESULTS: Eleven studies representing a total of 1248 patients were included in the review.A significant 41% relative risk reduction (RRR) in vertebral fractures across eight studies (RR 0.59, 95% CI 0.36 to 0.96) was found. The six secondary prevention trials demonstrated a significant RRR of 47% in vertebral fractures (RR 0.53, 95% CI 0.32 to 0.87) and a 5% absolute risk reduction (ARR); compared with the pooled result for the two primary prevention trials (RR 3.03, 95% CI 0.32 to 28.44), which was not significant. There were no statistically significant risk reductions for non-vertebral (RR 0.98, 95% CI 0.68 to 1.42), hip (RR 1.20, 95% CI 0.37 to 3.88) or wrist fractures (RR 0.87, 95% CI: 0.32 to 2.36). For adverse events, no statistically significant differences were found in the included studies. However, observational data has led to concerns regarding potential risk for upper gastrointestinal injury.
AUTHORS' CONCLUSIONS: Etidronate, at 400 mg per day, demonstrated a statistically significant and clinically important benefit in the secondary prevention of vertebral fractures. No statistically significant reductions in vertebral fractures were observed when it was used for primary prevention. In addition, no statistically significant reductions in non-vertebral, hip, or wrist fractures were found, regardless of whether etidronate was used for primary or secondary prevention. The level of evidence for all outcomes is Silver (www.cochranemsk.org.).
Authors:
G A Wells; A Cranney; J Peterson; M Boucher; B Shea; V Robinson; D Coyle; P Tugwell
Related Documents :
19864348 - Low rates of treatment in postmenopausal women with a history of low trauma fractures: ...
15045468 - Health-related quality of life after osteoporotic fractures.
19841028 - Effects of socioeconomic position on 30-day mortality and wait for surgery after hip fr...
10365538 - Risk factors for postoperative femoral fracture in cementless hip arthroplasty.
20876238 - Pregnane x receptor knockout mice display osteopenia with reduced bone formation and en...
22437628 - Zoledronic acid improves bone mineral density in paediatric spinal cord injury.
Publication Detail:
Type:  Journal Article; Meta-Analysis; Review     Date:  2008-01-23
Journal Detail:
Title:  The Cochrane database of systematic reviews     Volume:  -     ISSN:  1469-493X     ISO Abbreviation:  Cochrane Database Syst Rev     Publication Date:  2008  
Date Detail:
Created Date:  2008-02-06     Completed Date:  2008-04-14     Revised Date:  2013-06-28    
Medline Journal Info:
Nlm Unique ID:  100909747     Medline TA:  Cochrane Database Syst Rev     Country:  England    
Other Details:
Languages:  eng     Pagination:  CD003376     Citation Subset:  IM    
Affiliation:
University of Ottawa Heart Institute, Cardiovascular Research Reference Centre, Room H1-1, 40 Ruskin Street, Ottawa, Ontario, Canada K1Y 4W7. gawells@ottawaheart.ca
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Bone Density / drug effects
Bone Density Conservation Agents / adverse effects,  therapeutic use*
Etidronic Acid / adverse effects,  therapeutic use*
Female
Hip Fractures / prevention & control
Humans
Osteoporosis, Postmenopausal / drug therapy*,  prevention & control
Spinal Fractures / etiology,  prevention & control*
Wrist Injuries / prevention & control
Chemical
Reg. No./Substance:
0/Bone Density Conservation Agents; 2809-21-4/Etidronic Acid
Comments/Corrections
Update Of:
Cochrane Database Syst Rev. 2001;(4):CD003376   [PMID:  11687195 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Omega-3 polyunsaturated fatty acids (PUFA) for type 2 diabetes mellitus.
Next Document:  Cycle regimens for frozen-thawed embryo transfer.